| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 20, 2005
Accepted on April 26, 2006
From the Sections of Surgery (G.T.J., L.V.P., A.M.v.) and Medicine (I.P.K., J.W.S.C., G.T.W., M.M., M.J.A.W.), University of Otago, Dunedin, New Zealand.
* To whom correspondence should be addressed. E-mail: greg.jones{at}otago.ac.nz.
Objective--This study aimed to determine whether the plasma levels of matrix metalloproteinase-9 (MMP-9) or tissue inhibitor of metalloproteinases-1 (TIMP-1) were altered in patients with a history of symptomatic in-stent restenosis (ISR).
Methods and Results--A group of 158 patients with a history of ISR were compared with 128 symptom-free patients. Plasma samples and a detailed risk factor history were collected. Plasma samples were analyzed for pro-MMP-9 and latent MMP-9 and active MMP-9, latent MMP-3, and TIMP-1. Several variables were associated with ISR, including index coronary disease extent and severity (number of diseased vessels and American College of Cardiology/American Heart Association lesion classification), number, diameter, and total length of stent(s) inserted, and plasma high-density lipoprotein cholesterol. Plasma active MMP-9 (odds ratio, 1.96; 95% CI, 1.43 to 2.69) showed independent risk association with ISR. Patients with multiple sites of ISR had significantly higher levels of active MMP-9 compared with patients with only a single ISR lesion or no ISR.
Conclusion--Plasma active MMP-9 levels may be a useful independent predictor of bare metal stent ISR.
This article has been cited by other articles:
![]() |
A. Fischoeder, H. Meyborg, D. Stibenz, E. Fleck, K. Graf, and P. Stawowy Insulin augments matrix metalloproteinase-9 expression in monocytes Cardiovasc Res, March 1, 2007; 73(4): 841 - 848. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |